好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Novel Semi-Quantitative High Sensitivity ELISA for Detecting Anti-NMDA Receptor Autoantibodies in Serum and CSF
Autoimmune Neurology
P1 - Poster Session 1 (11:45 AM-12:45 PM)
8-013

To establish semi-quantitative high sensitivity ELISA for detecting anti-NMDA receptor (NMDAR) autoantibodies (autoAbs) from patients with anti-NMDAR encephalitis (ANRE).

AutoAbs targeting the N-terminal domain of the NR1 subunit (NR1-NTD) of the NMDA receptor (NMDAR) cause ANRE which is the most prevalent form of autoimmune encephalitis. A fixed cell based assay (fixed-CBA) using HEK293 cells expressing NMDAR NR1 protein is widely used for detecting anti-NMDAR IgG autoAbs. Although the fixed-CBA is well accepted in the field, it is less-sensitive in serum samples due to relatively high background staining and gives only antibody titers. Although ELISA is a standard assay to detect antibodies in general, anti-NMDAR autoAb detection has not been successfully demonstrated using regular peptide or protein ELISA.

A novel ELISA was developed using NR1-NTD protein (19-403 aa) with a C-terminal biotinylated Avi-tag as the antigen used for immobilization on streptavidin coated plates. ELISA sensitivity and specificity were assessed using monoclonal antibodies from ANRE patients (Ly et al. 2018). Serum and CSF samples from ANRE patients at the University of Texas Southwestern in both acute and recovery phase were tested by NR1-NTD ELISA and the results were compared with previous data obtained by clinically available fixed-CBA. 

After observing poor sensitivity with a typical random NTD-NR1 protein coating ELISA method, a unidirectional coating method was established to detect weak and low abundance mAbs from ANRE patients. Importantly, this ELISA detected IgG signals in serum samples that were originally judged negative by clinically acquired fixed-CBA from recovering ANRE patients who still had residual symptoms at blood sampling. The pseudo-concentrations of IgG were lower in these patients in recovery phase compared to acute phase.

Novel semi-quantitative high sensitivity NTD-NR1 ELISA may enable us to detect anti-NMDAR IgG autoAbs in serum samples from recovering ANRE patients who still suffer from residual anti-NMDAR autoAbs.

Authors/Disclosures
Mitsuyuki Matsumoto, PhD (Arialys Therapeutics, Inc.)
PRESENTER
Dr. Matsumoto has received personal compensation for serving as an employee of Arialys Therapeutics, Inc.. Dr. Matsumoto has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Arialys Therapeutics, Inc.. Dr. Matsumoto has or had stock in Arialys Therapeutics, Inc..Dr. Matsumoto has received intellectual property interests from a discovery or technology relating to health care.
Shanni Yamaki Shanni Yamaki has received personal compensation for serving as an employee of Arialys Therapeutics Inc. .
Roghiye Kazimi (Arialys) Roghiye Kazimi has nothing to disclose.
Vallari Eastman Vallari Eastman has nothing to disclose.
Amir Razai (Arialys) Amir Razai has received personal compensation for serving as an employee of Arialys .
Scott Snipas (Arialys) Scott Snipas has received personal compensation for serving as an employee of Arialys Therapeutics .
Mari Maurer (Arialys Therapeutics) Ms. Maurer has received personal compensation for serving as an employee of Arialys Therapeuticss, Inc.. Ms. Maurer has received personal compensation for serving as an employee of ESCAPE Bio. Ms. Maurer has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ReCode Therapeutics. Ms. Maurer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momentum Pharma. Ms. Maurer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ESCAPE Bio. Ms. Maurer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys Therapeutics.
Mathew Mitchell (Arialys Therapeutics, Inc.) Mr. Mitchell has received personal compensation for serving as an employee of Arialys Therapeutics.
Martin Jefson, PhD Dr. Jefson has received personal compensation for serving as an employee of Arialys Therapeutics. Dr. Jefson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Arialys Therapeutics.
Peter Flynn, PhD Dr. Flynn has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Artiva. Dr. Flynn has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Arialys.
Nancy Monson (University of Texas Southwestern) Nancy Monson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech, Inc.. Nancy Monson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenrAb, Inc.. Nancy Monson has stock in GenrAb, Inc.. The institution of Nancy Monson has received research support from NIH. Nancy Monson has received intellectual property interests from a discovery or technology relating to health care.
Benjamin M. Greenberg, MD, FAAN (UT Southwestern Medical Center) Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has or had stock in GenrAb.Dr. Greenberg has or had stock in Clene.Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.